Inhibrx Announces Participation in Upcoming Scientific Conference [Yahoo! Finance]
Inhibrx, Inc. (INBX)
Company Research
Source: Yahoo! Finance
company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference: Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.) ESMO Sarcoma and Rare Cancers Congress March 12 th th , 2026; Lugano Switzerland Title: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing Sarcoma Abstract number: 84MO Lead Author: Rashmi Chugh, M.D. (Presenting author: Ana Sebio, M.D., Ph.D.) Format: Mini oral session 1: Sarcoma presentation Date: Thursday, March 12 th Time: 11:30 am CET Location: Hall A at the Palazzo dei Congressi Lugano; Lugano, Switzerland The presentation will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of the event. About Inhibrx Biosciences, Inc. Inhi
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx Announces Participation in Upcoming Scientific ConferencePR Newswire
- Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]Seeking Alpha
- Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]Yahoo! Finance
INBX
Earnings
- 8/13/25 - Beat
INBX
Sec Filings
- 2/23/26 - Form 8-K
- 2/17/26 - Form SCHEDULE
- 2/11/26 - Form SCHEDULE
- INBX's page on the SEC website